Synoptical view

    Truffle investment
    € 15M
    Stock
    Pharnext is listed on EURONEXT GROWTH PARIS since 2016
pharmnext.jpg

Management team

daniel_cohen.jpg

Prof. Daniel Cohen

CEO

serge_fitoussi.jpg

Serge Fitoussi

CMO

Board of Directors

michel_de_rosen.jpg

Michel de Rosen

President

In summary

Pharnext has two flagship products in clinical development, one for the treatment of Charcot-Marie-Tooth disease type 1A, the other for the treatment of Alzeimer's disease. Pharnext has developed a new paradigm for drug discovery based on large genomic data and artificial intelligence: PLEOTHERAPY. The company identifies and develops synergistic drug combinations.

They talk about it

daniel_cohen.jpg

We are the first to have developed a product using artificial intelligence

News

Press Release
logo_pharnext_gb.jpg

Pharnext Announces Identification of a Large Set of Frequently Prescribed Drugs to be Repurposed for Fighting COVID-19

pkmed.jpg

Next start-up

PKMed